病理学与病理生理学 教授
职称：教授
学科专业：病理学与病理生理学
研究方向：
1.重大疾病的外泌体液体检测和免疫治疗；
2.嵌合RNA和突变非依赖肿瘤；
3.肿瘤新型药物靶点和癌症筛查靶标
行政职务：
肿瘤精准医学和病理研究所所长
教育部肿瘤分子生物学重点实验室副主任
电子邮箱：haozhang@jnu.edu.cn
个人简介：
张灏教授，暨南大学基础医学与公共卫生学院教授、博士生导师、博士后指导教授、肿瘤精准医学和病理研究所所长、教育部肿瘤分子生物学重点实验室副主任。专注我国高发恶性肿瘤的诊治的转化研究和应用，提出RNA异常剪接及其产物非突变依赖性肿瘤发现嵌合RNA及其翻译蛋白作为驱动机制，并以此为诊断靶标和治疗靶点开展了外泌体液体活检和免疫治疗，包括无创性外泌体检测、基于嵌合RNA的外泌体疫苗、外泌体包裹的抗体导向RNA药物等。获批十余项发明专利，荣获《广东省科技进步奖二等奖》、《广东省医学科技奖二等奖》、《河南省科技进步一等奖》、《中国产学研合作创新奖》、《金博奖全球高层人才科技创新大赛金奖》、《全国十佳消化道领域临床研究金奖》、《中国研究型医院学会医学研究创新奖一等奖》、《Wiley中国开放科学高贡献奖》、《2022中国生物医药企业最具创新力50强奖》等。担任中国抗癌协会肿瘤标志专业委员会外泌体技术专家委员会（CSEMV）主委，《外泌体研究转化和临床应用专家共识》专家组组长。Annals of Medicine（Taylor & Francis 出版社）肿瘤学主编，Cancer Letters（Elsevier 出版社）编委，Extracellular Vesicles & Circulating Nucleic Acids（OAE 出版社）编委，Extracellular Vesicle （Elsevier出版社）编委，Scientific Report（Nature出版社）编委。中国抗癌协会肿瘤标志专业委员会常务委员，中国抗癌协会肿瘤标志物专业委员会常委，中国抗癌协会肿瘤代谢委员会常委，中国临床肿瘤协会胰腺癌专家委员会常委，亚太医学生物免疫学会肿瘤学分会副主委，广东省抗癌协会肿瘤代谢委员会副主委, 广东省抗癌协会肿瘤标志物专业委员会副主委, 广东省抗癌协会抗肿瘤药物专业委员会副主委。
1994-1999，日本岛根医科大学，博士，发育生物学/细胞生物学
1988-1994，中国医科大学附属盛京医院，住院医/主治医/讲师，内科内分泌科
1984-1987，中国医科大学，硕士，内科内分泌学
1979-1984，中国医科大学，本科，临床医学
2018-至今，暨南大学，基础医学与公共卫生学院教授、肿瘤精准医学和病理研究所所长、教育部肿瘤分子生物学重点实验室副主任
2008-2018，汕头大学医学院，教授，附属肿瘤医院/肿瘤研究中心
2004-2008，美国UT MD Anderson 癌症中心，讲师，分子肿瘤学系/遗传系
1999-2004，美国贝勒医学院，博士后研究员，分子细胞学系
近年来代表性论文(*通讯作者)
1.Li K#,Lin YS#,Xiong X,Zhou F,Guo Y,Li J,Chen Y,Zhang D, Bremer E,Yeung SJ,Zhang H*.Salivary extracellular miRNAs for early detection and prognostication of esophageal cancer: a clinical study.Gastroenterology.2023.
2.Xiong X#,Ke X#,Wang L#,Yao Z,Guo Y,Zhang X,Chen Y,Pang CP,Schally AV*,Zhang H*.Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target.Proc Natl Acad Sci U S A.2020 Mar;117(12):6726-6732.
3.Xiong X#,Ke X#,Wang L,Lin Y,Wang S,Yao Z,Li K,Luo Y,Liu F,Pan Y,Yeung SJ,Helfrich W,Zhang H*.Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles.J Extracell Vesicles.2022 Aug;11(8):e12243.
4.Wang S#,Lin Y#,Xiong X,Wang L,Guo Y,Chen Y,Chen S,Wang G,Lin P,Chen H,Yeung SJ*,Bremer E,Zhang H*.Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial.Clin Cancer Res.2020 Sep;26(18):4921-4932.
5.Li K#,Lin Y,Luo Y,Xiong X,Wang L,Durante K,Li J,Zhou F,Guo Y,Chen S,Chen Y,Zhang D,Yeung SJ,Zhang H*.A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma:a multicenter prospective study.Mol Cancer.2022 Jan;21(1):21.
6.Yao Z#,Dong H#,Zhu J#,Du L#,Luo Y#,Liu Q,Liu S,Lin Y,Wang L,Wang S,Wei W,Zhang K,Huang Q,Yu X,Zhao W,Xu H,Qiu X,Pan Y,Huang X,Yeung SC,Zhang D,Zhang H*.Age-related decline in hippocampal tyrosine phosphatase PTPRO is a mechanistic factor in chemotherapy-related cognitive impairment.JCI Insight.2023.
7.Gan J,Ke X,Jiang J,Dong H,Yao Z,Lin Y,Lin W,Wu X,Yan S,Zhuang Y,Chu WK,Cai R,Zhang X,Cheung HS,Block NL,Pang CP,Schally AV*,Zhang H*.Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-κB signaling. Proc Natl Acad Sci U S A.2016 Dec;113(51):14745-14750.
8.Lin Y#,Dong H#,Deng W#,Lin W,Li K,Xiong X,Guo Y,Zhou F,Ma C,Chen Y,Ren H,Yang H,Dai N,Ma L,Meltzer SJ,Yeung SJ,Zhang H*.Evaluation of Salivary Exosomal Chimeric GOLM1-NAA35 RNA as a Potential Biomarker in Esophageal Carcinoma.Clin Cancer Res.2019 May;25(10):3035-3045.
9.Wang L#,Du L,Xiong X,Lin Y,Zhu J,Yao Z,Wang S,Guo Y,Chen Y,Geary K,Pan Y,Zhou F,Gao S,Zhang D,Yeung SJ,Zhang H*.Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.Oncogene.2021 Mar;40(11):1974-1987.
10.Lin Y#,Wang S#,Bremer E*,Zhang H*.Harnessing the soil: reshaping the tumor microenvironment towards an antitumor immune state by low‐dose metformin.Cancer Commun.2021 Aug;41(8):637-641.
11.Dong H#,Xu J#,Li W#,Gan J,Lin W,Ke J,Jiang J,Du L,Chen Y,Zhong X,Zhang D,Yeung SJ,Li X,Zhang H*.Reciprocal androgen receptor/interleukin-6 crosstalk drives oesophageal carcinoma progression and contributes to patient prognosis.J Pathol.2017 Mar;241(4):448-462.
12.Wang L#,Xiong X,Yao Z,Zhu J,Lin Y,Lin W,Li K,Xu X,Guo Y,Chen Y,Pan Y,Zhou F,Fan J,Chen Y,Gao S,Jim Yeung SC,Zhang H*.Chimeric RNA ASTN2-PAPPAas aggravates tumor progression and metastasis in human esophageal cancer.Cancer Lett.2021 Mar;501:1-11.
13.Du L#,Wang L,Gan J,Yao Z,Lin W,Li J,Guo Y,Chen Y,Zhou F,Jim Yeung SC,Coppes RP,Zhang D,Zhang H*.MTA3 Represses Cancer Stemness by Targeting the SOX2OT/SOX2 Axis.iScience.2019 Dec;22:353-368.
14.Dong H#,Ma L#,Lin Wan,Gan J,Chen C,Yao Z,Du L,Zheng L,Ke C,Huang X,Song H,Kumar R,Yeung SC,Zhang H*.PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2.
Oncogene.2017 Jan;36(3):410-422.
15.Wang L#,Li K#,Lin X#,Yao Z,Wang S,Xiong X,Ning Z,Wang J,Xu X,Jiang Y,Liu D,Chen Y,Zhang D,Zhang H*.Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis.Cancer Lett.2019 Jul;450:22-31.
16.Chang L#,Ni J#,Zhu Y,Pang B,Graham P,Zhang H*,Li Y*.Liquid biopsy in ovarian cancer: recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression.Theranostics.2019 May;9(14):4130-4140.
17.Su JF#,Concilla A,Zhang DZ,Zhao F,Shen, FF,Zhang H*,Zhou FY*.PIWI-interacting RNAs.Mitochondria-based biogenesis and functions in cancer.Genes Dis.2020 Oct;8(5):603-622.
18.Feng Y#,Ke C#,Tang Q#,Dong H,Zheng X,Lin W,Ke J,Huang J,Yeung SC,Zhang H*.Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling.Cell Death Dis.2014 Feb;5(2):e1088.
19.Tamiya H#,Kim H#,Klymenko O,Kim H,Feng Y,Zhang T,Han JY,Murao A,Snipas SJ,Jilaveanu L,Brown K,Kluger H,Zhang H,Iwai K,Ronai AZ.SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth.J Clin Invest.2018 Jan;128(1):517-530.
20.Chu WK#,Law KS,Chan SO,Yam JC,Chen LJ,Zhang H,Cheung HS,Block NL,Schally AV,Pang CP.Antagonists of growth hormone-releasing hormone receptor induce apoptosis specifically in retinoblastoma cells.Proc Natl Acad Sci U S A.2016 Dec;113(50):14396-14401.
21.Zhou C*,Wu YL,Chen G,Liu X,Zhu Y,Lu S,Feng J,He J, Han B,Wang J,Jiang G,Hu C,Zhang H,Cheng G,Song X, Lu Y,Pan H,Zheng W,Yin AY.BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.J Clin Oncol.2015 Jul;33(19):2197-204.
22.Chen T#,Chen Q,Xu Y,Zhou Q Zhu J,Zhang H,Wu Q,Xu J,Yu C*.SRC-3 is required for CAR-regulated hepatocyte proliferation and drug metabolism.J Hepatol.2012 Jan;56(1):210-217.
23.Tong Z#,Li M#,Wang W,Mo P,Yu L,Liu K,Ren W,Li W,Zhang H,Xu J,Yu C*.Steroid Receptor Coactivator 1 Promotes Human Hepatocellular Carcinoma Progression by Enhancing Wnt/beta-Catenin Signaling.J Biol Chem.2015 Jul;290(30):18596-608.
24.Peng M#,Zhang H,Jaafar L,Risinger JI,Huang S,Mivechi NF,Ko L*.Human ovarian cancer stroma contains luteinized theca cells harboring tumor suppressor gene GT198 mutations.J Biol Chem.2013 Nov;288(46):33387-97.
25.Ploeg E,Ke X,Britsch I,Hendriks M,Van der Zant F,Kruijff S,Samplonius D,Zhang H*,Helfrich W*.Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles.Cancer Letters.2021 Aug;521:109-118.
26.Xu B,Jiang X,Jing Xiong,Jun Lan,Yuan Tian,Linhai Zhong,Xinquan Wang,Ning Xu,Hanwei Cao,Wenqing Zhang,Zhang H,Xiaoting Hong,Yan-Yan Zhan*,Yandong Zhang*,Tianhui Hu*.Structure-Activity Relationship Study Enables the Discovery of a Novel Berberine Analogue as the RXRα Activator to Inhibit Colon Cancer.J Med Chem.2020 Jun;63(11):5841-5855.
27.Bhagelu R.Achyut,Zhang H*,Kartik Angara,Nahid F.Mivechi,Ali S.Arbab,Lan Ko*.Oncoprotein GT198 Vaccination Delays Tumor Growth in MMTV-PyMT Mice.Cancer Lett.2020 Apr;476:57-66.
28.Yao Z#,Du L#,Xu M,Li K,Guo H,Ye G,Zhang D,Coppes RP,Zhang H*.MTA3-SOX2 Module Regulates Cancer Stemness and Contributes to Clinical Outcomes of Tongue Carcinoma.Front Oncol.2019 Aug;9:816.
29.Ke X,Xiong X,Lin Y,Zhang H*.Chimeric RNA and Exosomes-Based Liquid Biopsy.Methods Mol Biol.2020;2079:211-218.
30.Wang W#,Lim KG#,Feng M,Bao Y,Lee PL,Cai Y,Chen Y,Zhang H,Marzese D,Hoon DSB,Yu Q*.KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer.Mol Cancer Ther.2018 Sep;17(9):1973-1983.
31.Li Z#,Zou X#,Xie L,Chen H,Chen Y, Yeung SC,Zhang H*.Personalizing risk stratification by addition of PAK1 expression to TNM staging: improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma.Int J Cancer.2015 Apr;136(7):1636-1645.
32.Zhang H*,Lin W,Kannan K, Luo L,Li J,Chao PW,Wang Y,Chen YP,Gu J,Yen L*.Aberrant chimeric RNA GOLM1-MAK10 encoding a secreted fusion protein as a molecular signature for human esophageal squamous cell carcinoma.Oncotarget.2013 Nov;4(11),2135-2143.
33.Yu J#,Lin Y#,Xiong X#,Li K, Yao Z,Dong H,Jiang Z,Yu D,Yeung SJ,Zhang H*.Detection of Exosomal PD-L1 RNA in Saliva of Patients With Periodontitis.Front Genet.2019 Mar;10:202.
34.Wang L,Li W,Li K,Guo Y,Liu D,Yao Z,Lin X,Li S, Jiang Z,Liu Q,Jiang Y,Zhang B,Chen L,Zhou F,Ren H, Lin D,Zhang D,Yeung SJ,Zhang H*.The oncogenic roles of nuclear receptor coactivator 1 in human esophageal carcinoma.Cancer Med.2018 Oct;7:5205-5216.
35.Tang Q,Li G,Wei X,Zhang J,Chiu JF,Hasenmayer D,Zhang D,Zhang H*.Resveratrol-induced apoptosis is enhanced by inhibition of autophagy in esophageal squamous cell carcinoma.Cancer Lett.2013 Aug;336(2):325-337.
36.You Y,Chen Y,Zheng X,Meltzer SJ,Zhang H*.Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients.Cancer Lett.2012 Feb;315(2):138-144.
37.Zhang H,Singh RR,Talukder AH,Kumar R*.Metastatic tumor antigen 3 is a direct corepressor of the Wnt4 pathway.Genes Dev.2006 Nov;20(21):2943-2948.
38.Zhang H,Kuang SQ,Liao L,Zhou S,Xu J*.Haploid inactivation of the amplified-in-breast cancer 3 coactivator reduces the inhibitory effect of peroxisome proliferator-activated receptor gamma and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice.Cancer Res.2004 Oct;64(19):7169-7177.
39.Zhang H,Stephens LC,Kumar R*.Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.Clin Cancer Res.2006 Mar;12(5):1479-1486.
40.Kumar R*,Zhang H,Holm C,Vadlamudi RK,Landberg G,Rayala SK*.Extranuclear coactivator signaling confers insensitivity to tamoxifen.Clin Cancer Res.2009 Jun;15(12):4123-4130.
41.Wang RA,Zhang H,Balasenthil S,Medina D,Kumar R*.PAK1 hyperactivation is sufficient for mammary gland tumor formation.Oncogene.2006 May;25(20):2931-2936.
42.Goo YH,Na SY,Zhang H,Xu J,Hong S,Cheong J,Lee SK,Lee JW*.Interactions between activating signal cointegrator-2 and the tumor suppressor retinoblastoma in androgen receptor transactivation.J Biol Chem.2004 Feb;279(8):7131-5.
43.Kuang SQ,Liao L,Zhang H,Pereira FA,Yuan Y,DeMayo FJ,Ko L,Xu J*.Deletion of the cancer-amplified coactivator AIB3 results in defective placentation and embryonic lethality.J Biol Chem.2002 Nov;277(47):45356-60.
44.Kuang SQ,Liao L,Zhang H,Lee AV,O'Malley BW,Xu J*.AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice.Cancer Res. 2004 Mar,64(5):1875-1885. (IF: 13.312)
45. Anupama E.Gururaj*,Rajesh R.Singh*#,Suresh K.Rayala*#,Caroline Holm, Petra den Hollander*,Zhang H*,Seetharaman Balasenthil*,Amjad H.Talukder*,Goran Landberg,and Rakesh Kumar*.MTA1,a transcriptional activator of breast cancer amplified sequence 3.Proc Natl Acad Sci U S A.2006 Apr,103(17):6670-6675. (
46.Klionsky DJ et al:Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).Autophagy.2016,12(1):1-222.
47.Zhang S,Zeng D,Peng Y,Yang Y,Zhuang X,Li Z,Wang M,Chen L,Zhang H*.Cancer-related fatigue and chemotherapy-associated adverse effects:correlation with TNF-α,IL-1 and 17-hydroxycorticosteroids.Future Oncol.2014 Jan;10(9):1619-26.
48.Zheng L#,Wang L#,Gan J,Zhang H*.RNA activation:promise as a new weapon against cancer.Cancer lett.2014 Dec;355(1):18-24.
49.Ning Z,Gan J,Chen C,Zhang D,Zhang H*.Molecular functions and significance of the MTA family in hormone-independent cancer.Cancer Metastasis Rev. 2014 Dec,33(4):901-919.
50.Xingli Dong,Xupeng Bai,Jie Ni,Zhang H,Wei Duan,Peter GrahamYong Li*.Exosomes and breast cancer drug resistance.Cell Death & Disease.2020 Nov;11(11):987.
51.Chu YL,Li H,Ng PLA,Kong ST,Zhang H,Lin Y,Tai WCS, Yu ACS,Yim AKY,Tsang HF,Cho WCS,Wong SCC*.The potential of circulating exosomal RNA biomarkers in cancer.Expert Rev Mol Diagn.2020 Jul;20(7):665-678.
52.Ma L,Yao Z,Deng W,Zhang D,Zhang H*.The Many Faces of MTA3 Protein in Normal Development and Cancers.Curr Protein Pept Sci. 2016,17(8):726-734.
53.Du L#,Ning Z#,Zhang H*,Liu F*.Corepressor metastasis-associated protein 3 modulates epithelial-to-mesenchymal transition and metastasis.Chin J Cancer.2017 Mar,36(1):28.
54.Xie, F.,Dong, H.,&Zhang H*.Regulatory Functions of Protein Tyrosine Phosphatase Receptor Type O in Immune Cells.Front Immunol.2021 Nov;12.
55.Shuhong Wang#,Yusheng Lin,Yishi Zhang,Xiaofu Qiu,Yunlong Pan,Sai-Ching Jim Yeung h,Zhang H*.Complex RNA world in small extracellular vesicles for liquid biopsy in cancer management.Extracellular Vesicle.2022.10.
56.林宇晟,甘进锋,江钰琛,王飞寒,张灏*.外泌体标志物和肿瘤液体活检的研究进展及现状。中国癌症防治杂志, 2019, 11(02): 99-103.
57.刘情,郑琳,张灏*.人源性肿瘤组织异种移植(PDX)模型的研究进展。转化医学杂志, 2014, 10. 3969, 2095-3097.
58.黄裔腾,殷秀凯,钟雪云,张灏*.食管鳞癌模式动物的研究进展.世界华人消化杂志,2011,19(16):1704-1710.
59.李宗泰,张灏*.外周血游离DNA甲基化检测: 食管鳞癌早期诊疗的新机遇.转化医学杂志,2012,1(1)：45-48.
60.李金平, 宁志丰, 刘复兴, 张灏*: 老药新用, 小分子药物二甲双胍的抗肿瘤研究进展.中国生化药物杂志,2016,36(8):16-21
61.王姝宏,余幼林，李凯，林宇晟，甘进锋，谢飞凌，李勇，黄思铨,张灏*.外泌体在肿瘤和极端条件中的作用和检测。中国癌症防治杂志,2020,12(3)：239-243.
62.吴晓，杨海军，高社干,周福有，张灏*.原发性食管小细胞癌的研究及诊疗现状.食管疾病,2020,2(1),8-12.
63.张灏等。《外泌体研究、转化和临床应用专家共识》，转化医学杂志，2018。
1.《Encyclopedia of Cancer 》(癌症百科全书）《Springer出版社》编委；
2.《肿瘤急症治疗例析》《人民卫生出版社》主编，2020；
3.《Chimeric RNA: Methods and Protocols》《Springer出版社》编委，2020年；
4.《乳腺癌》《人民卫生出版社》副主编；
5.《细胞外囊泡》《科学出版社》编委，2019年；
6.《肿瘤标志物》《人民卫生出版社》编委，2022年；
7.《肿瘤标志物通讯》（外泌体专刊）《中国抗癌协会出版》主编，2018年。
1. 食管癌肿瘤标志物及液体活检的应用与开发，广东省科技厅，广东省科学技术科技进步奖，二等奖，2020年；
2. 牙龈卟啉单胞菌诱发微生态失衡促进食管癌发生发展的机制及应用，河南省科学技术进步奖，一等奖，2023年；
3. 食管癌早期诊断和治疗新方法的转化研究，广东省医学会，广东省医学会科技进步奖励，二等奖，2019年；
4. 低剂量二甲双胍重编程食管癌免疫微环境：II期临床研究 获奖人；张灏教授团队（暨南大学医学院）2020年度十佳消化道领域临床研究金奖，Gastroenterology Report, 《中华胃肠外科杂志》《中华炎性肠病杂志》；
5. 中国产学研合作创新与促进奖，获奖人；张灏教授，中国产学研合作促进会,2021年；
6. 上消化道肿瘤诊断和治疗新方法的转化研究，汕头市科学技术奖励，一等奖，2018年；
7.《金博奖全球高层人才科技创新大赛金奖》，2021年
8.《中国研究型医院学会医学研究创新奖一等奖》2022年
9.《Wiley中国开放科学高贡献奖》2022年
10.《2022中国生物医药企业最具创新力50强奖》2022年
指导团队青年成员获得过如下项目:
1. 2020年第三届粤港澳大湾区医学与健康发展论坛获得一等奖
2. 2020年暨南大学生命科学创新奖获得二等奖
3. 2021年第四届粤港澳大湾区医学与健康发展论坛获得二等奖
4. 2021年暨南大学生命科学创新奖获得二等奖*
1.中国抗癌协会肿瘤标志专业委员会外泌体技术专家委员会（CSEMV）主委
2.《外泌体研究转化和临床应用专家共识》专家组组长
3.Cancer Letters（Elsevier 出版社）和Scientific Report（Nature出版社）编委
4.（Extracellular Vesicles & Circulating Nucleic Acids）和（Extracellular Vesicle）编委
5.Annals of Medicine（Taylor & Francis 出版社）肿瘤学主编
6.Cancer Research，Clinical Cancer Research,Oncogene & PNAS等杂志的审稿专家
7.《胰腺癌诊治指南》撰写组专家
8.中国抗癌协会肿瘤标志专业委员会常务委员
9.中国抗癌协会肿瘤标志物专业委员会常委
10.中国抗癌协会肿瘤代谢委员会常委
11.中国临床肿瘤协会胰腺癌专家委员会常委
12.亚太医学生物免疫学会肿瘤学分会副主委
13.广东省抗癌协会肿瘤代谢委员会副主委
14.广东省抗癌协会肿瘤标志物专业委员会副主委
15.广东省抗癌协会抗肿瘤药物专业委员会副主委
